Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novavax announces positive top-line data from dose-confirmatory phase 2 clinical trial of RSV vaccine candidate in women of childbearing age


Monday, 28 Apr 2014 04:13pm EDT 

Novavax Inc:Says positive top-line safety and immunogenicity data from its RSV-F protein nanoparticle vaccine candidate in a Phase 2 clinical trial in women of childbearing age.Randomized, blinded, placebo-controlled Phase 2 study was designed to evaluate the immunogenicity and safety of multiple formulations of Novavax' RSV-F protein nanoparticle vaccine adjuvanted with aluminum phosphate.Primary outcome of the trial was safety and immune response (measured by levels of serum IgG antibody specific for the F protein).These top-line data relate to the safety and immunogenicity over the 91-day period following first immunization and support Novavax' maternal immunization strategy. 

Company Quote

4.48
-0.03 -0.67%
21 Aug 2014